不列颠哥伦比亚省局部晚期外阴癌或阴道癌患者的治疗模式与结局
该回顾性病历 review 纳入2000-2017年不列颠哥伦比亚省688例外阴癌(n=560,81%)或阴道癌(n=128,19%)患者,中位诊断年龄68(27-98)岁。多因素分析显示外阴癌死亡风险高于阴道癌(HR:1.50,p=0.042)。接受根治性放疗者中,同步化疗与否的总生存无显著差异;接受放疗的外阴癌患者加化疗未显著改善总生存(HR:0.989,p=0.957),阴道癌患者放化疗较单纯放疗亦无显著总生存获益(HR:0.720,p=0.331)。
要点
- 外阴癌死亡风险高于阴道癌(HR:1.50,p=0.042)。
- 外阴癌根治性放疗加同步化疗未显著改善总生存(HR:0.989,p=0.957)。
- 阴道癌放化疗较单纯放疗总生存无显著获益(HR:0.720,p=0.331)。
核心结论
- 在这项回顾性研究中,外阴癌或阴道癌患者接受放化疗与单纯放疗相比,生存无显著改善。
- 需要未来研究探索治疗这些癌症的新疗法以改善患者结局。
研究设计与样本
- 回顾性病历 review,纳入2000-2017年诊断为外阴癌或阴道癌的患者。
- 共纳入688例患者,其中外阴癌560例(81%),阴道癌128例(19%)。
- 中位诊断年龄为68(27-98)岁。
- 采用描述性统计总结人口学因素,采用Kaplan-Meier曲线、log-rank检验和多因素分析(含风险比HR)比较手术、放疗和放化疗之间的生存结局。
主要发现
- 多因素生存分析中,外阴癌与更高的死亡可能性相关(HR:1.50,p=0.042),对照为阴道癌。
- 接受根治性放疗的外阴癌患者中,同步化疗者中位总生存为63.8个月,无化疗者为46.3个月(p=0.75)。
- 接受根治性放疗的阴道癌患者中,同步化疗者中位总生存为100.4个月,无化疗者为66.6个月(p=0.31)。
- 接受放疗的外阴癌患者(n=224)中,加用化疗(n=100)与总生存改善无统计学显著关联(HR:0.989,p=0.957)。
- 接受放化疗的阴道癌患者(n=51)较接受放疗者(n=49)无显著总生存获益(HR:0.720,p=0.331)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: As vulvar and vaginal cancers are rare malignancies, treatment is extrapolated from the cervical cancer field. Further studies are necessary to evaluate whether surgery, radiotherapy (RT), or combined chemoRT is most beneficial. METHODS: A retrospective chart review was conducted on patients diagnosed with vulvar or vaginal cancer in 2000-2017. Descriptive statistics was used to summarize demographic factors. Kaplan-Meier curves, log-rank tests, multivariate analysis with hazard ratios (HR) were conducted to compare survival outcomes, including overall survival (OS), disease-free survival, and cancer-specific survival, between surgery, RT, and chemoRT. RESULTS: This study included 688 patients with either vulvar (n = 560, 81%) or vaginal cancer (n = 128, 19%). Median age of diagnosis was 68 (27-98) years. In multivariate survival analysis, vulvar cancer was associated with more likelihood of death (HR: 1.50, p = 0.042) compared to vaginal cancer. For patients who received definitive RT, median OS was 63.8 months with concurrent chemotherapy vs. 46.3 months without for vulvar cancer (p = 0.75); for vaginal, median OS 100.4 with chemotherapy vs. 66.6 months without (p = 0.31). For vulvar cancer patients who received RT (n = 224), adding chemotherapy (n = 100) was not associated with statistically significant OS improvement (HR: 0.989, p = 0.957). Similarly, vaginal cancer patients who received chemoRT (n = 51) did not have significant OS benefit (HR: 0.720, p = 0.331) over patients who received RT (n = 49). CONCLUSIONS: In this retrospective study, chemoRT was not associated with significant improvements in survival compared to RT in vulvar or vaginal cancer. Future studies investigating novel therapies to treat these cancers are needed to improve patient outcomes.
引用
- Leung E, Tremblay C, Liao D, et al. Treatment patterns and outcomes of patients with locally advanced vulvar or vaginal cancer in British Columbia. Gynecol Oncol. 2023. PMID: 37348429. doi:10.1016/j.ygyno.2023.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。